COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Valuation Ratios Analysis including PE, PB, PS, EV/EBITDA. Analyze if 3349.T stock is undervalued compared to peers/competitors, industry and sector standards or based on Value Investing Principles.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Valuation Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.

Price-to-Earnings Ratio (P/E)

4.87

Decreased from previous period

P/E of 4.87 versus zero earnings in Healthcare. Walter Schloss would verify earnings quality.

Price-to-Sales Ratio (P/S)

0.53

Decreased from previous period

P/S less than half the Healthcare median of 5.34. Walter Schloss would verify if this discount reflects fixable issues. Check margins versus peers.

Price-to-Book Ratio (P/B)

1.13

Decreased from previous period

P/B 50-90% of Healthcare median of 1.75. Mohnish Pabrai would examine if this discount presents opportunity.

Price-to-Free Cash Flow Ratio

4.56

Increased from previous period

P/FCF of 4.56 versus zero FCF in Healthcare. Walter Schloss would verify cash flow quality.

Price-to-Operating Cash Flow Ratio

3.79

Increased from previous period

P/OCF of 3.79 versus zero operating cash flow in Healthcare. Walter Schloss would verify operational quality.

Price-to-Fair Value

1.13

Decreased from previous period

Fair value ratio 50-90% of Healthcare median of 1.75. Mohnish Pabrai would examine if this gap presents opportunity.

Earnings Yield

5.13%

Increased from previous period

Earnings yield exceeding 1.5x Healthcare median of 0.11%. Joel Greenblatt would investigate if high yield reflects hidden value.

Free Cash Flow Yield

21.91%

Increased from previous period

FCF yield of 21.91% versus zero FCF in Healthcare. Walter Schloss would verify cash flow quality.

Select Chart Metric:

3349.T Valuation Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Price-to-Earnings Ratio (P/E)

4.87

Decreased from previous period

P/E of 4.87 versus zero earnings in Healthcare. Walter Schloss would verify earnings quality.

Price-to-Sales Ratio (P/S)

0.53

Decreased from previous period

P/S less than half the Healthcare median of 5.34. Walter Schloss would verify if this discount reflects fixable issues. Check margins versus peers.

Price-to-Book Ratio (P/B)

1.13

Decreased from previous period

P/B 50-90% of Healthcare median of 1.75. Mohnish Pabrai would examine if this discount presents opportunity.

Price-to-Free Cash Flow Ratio

4.56

Increased from previous period

P/FCF of 4.56 versus zero FCF in Healthcare. Walter Schloss would verify cash flow quality.

Price-to-Operating Cash Flow Ratio

3.79

Increased from previous period

P/OCF of 3.79 versus zero operating cash flow in Healthcare. Walter Schloss would verify operational quality.

Price-to-Fair Value

1.13

Decreased from previous period

Fair value ratio 50-90% of Healthcare median of 1.75. Mohnish Pabrai would examine if this gap presents opportunity.

Earnings Yield

5.13%

Increased from previous period

Earnings yield exceeding 1.5x Healthcare median of 0.11%. Joel Greenblatt would investigate if high yield reflects hidden value.

Free Cash Flow Yield

21.91%

Increased from previous period

FCF yield of 21.91% versus zero FCF in Healthcare. Walter Schloss would verify cash flow quality.

Select Chart Metric: